IDO1-IN-33 

IDO1-IN-33 (Compound YC-16) is a IDO1 inhibitor (with an IC₅₀ of 0.18 μM for IDO1 in HeLa cells). IDO1-IN-33 acts as an apo-IDO1 inhibitor by slowly and competitively displacing heme from mature holo-IDO1 and rapidly binding to the heme-binding site of immature apo-IDO1, without altering the expression level of IDO1. IDO1-IN-33 can be used for the research of hepatocellular carcinoma, non-small cell lung cancer, triple-negative breast cancer, and cervical cancer^[1].

IDO1-IN-33 (0.5 μM) potently inhibits IDO1 activity in HeLa cells, with an IC₅₀ of 0.18 ± 0.01 μM, and shows no significant cytotoxicity^[1].
IDO1-IN-33 (48 h) potently inhibits IDO1 activity in multiple human tumor cell lines (HepG2, A549, MDA-MB-231), with corresponding IC₅₀ values of 216.25 ± 12.8 nM, 115.9 ± 1.13 nM and 135.25 ± 12.37 nM, respectively, and shows no significant cytotoxicity^[1].
IDO1-IN-33 (0.05-0.4 μM; 48 h) does not regulate the expression of IDO1 mRNA in HeLa cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

432.95

C₂₅H₂₅ClN₄O

CCCC(NC(C1=CC=C(Cl)C=C1)=O)C(N=C2)=CN2CCC3=CC=NC4=C3C=CC=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wu JH, et al. Discovery of imidazole-based apo-IDO1 inhibitors: rational design, synthesis, and biological evaluation. Bioorg Med Chem Lett. Published online February 13, 2026.  [Content Brief]